News
Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback